These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

644 related items for PubMed ID: 9549924

  • 1. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
    Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Mordini N, Berisso G, Bregante S, Bacigalupo A.
    Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
    [Abstract] [Full Text] [Related]

  • 2. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S, Zikos P, Van Lint MT, Tedone E, Occhini D, Gualandi F, Lamparelli T, Mordini N, Berisso G, Bregante S, Bruno B, Bacigalupo A.
    Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
    [Abstract] [Full Text] [Related]

  • 3. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality.
    Bacigalupo A, Tedone E, Isaza A, Soracco M, Van Lint MT, Sanna A, Frassoni F, Occhini D, Gualandi F, Lamparelli T.
    Bone Marrow Transplant; 1995 Jul; 16(1):155-61. PubMed ID: 7581116
    [Abstract] [Full Text] [Related]

  • 4. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, Weisdorf DJ.
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [Abstract] [Full Text] [Related]

  • 5. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience.
    Bacigalupo A, Zikos P, Van Lint MT, Valbonesi M, Lamparelli T, Gualandi F, Occhini D, Mordini N, Bregante S, Berisso G, Vitale V, Sessarego M, Marmont AM.
    Exp Hematol; 1998 May; 26(5):409-14. PubMed ID: 9590657
    [Abstract] [Full Text] [Related]

  • 6. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T, Van Lint MT, Gualandi F, Occhini D, Barbanti M, Sacchi N, Ficai G, Ghinatti C, Ferrara GB, Delfino L, Pozzi S, Morabito A, Zikos P, Vitale V, Corvo R, Frassoni F, Bacigalupo A.
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [Abstract] [Full Text] [Related]

  • 7. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
    Huang XJ, Xu LP, Ren HY, Zhang YC, Guo NL, Lu DP.
    Zhonghua Yi Xue Za Zhi; 2003 May 10; 83(9):766-9. PubMed ID: 12899755
    [Abstract] [Full Text] [Related]

  • 8. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ, Ho WG, Bartoni K, Champlin RE.
    Bone Marrow Transplant; 1993 Sep 10; 12(3):283-8. PubMed ID: 8241988
    [Abstract] [Full Text] [Related]

  • 9. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 10. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation.
    Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H, Iida H, Shimokawa T, Kohno A, Mizuta S, Maruyama F, Wakita A, Kitaori K, Yano K, Hamaguchi M, Hamajima N, Morishima Y, Kodera Y, Sao H, Morishita Y.
    Bone Marrow Transplant; 2003 Oct 01; 32(8):801-7. PubMed ID: 14520425
    [Abstract] [Full Text] [Related]

  • 11. Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation.
    Martino R, Rovira M, Carreras E, Solano C, Jorge S, De La Rubia J, Caballero MD, de Oteyza JP, Zuazu J, Moraleda JM, Ojeda E, Ferrá C, Serrano D, De La Cámara R, Urbano-Ispízua A, Brunet S, AlloPBSCT and Infectious/Non-infectious Complications Subcommittes of the Grupo Español de Trasplante Hematopoyético (GETH).
    Haematologica; 2001 Oct 01; 86(10):1075-86. PubMed ID: 11602414
    [Abstract] [Full Text] [Related]

  • 12. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, Linker C, Kaizer H, Lazarus HM, Petersen FB, Cowan MJ, Ho WG, Wingard JR, Schiller GJ, Territo MC, Jiao J, Petrarca MA, Tonetta SA.
    Bone Marrow Transplant; 2001 Jul 01; 28(2):187-96. PubMed ID: 11509937
    [Abstract] [Full Text] [Related]

  • 13. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
    Bordon V, Bravo S, Van Renterghem L, de Moerloose B, Benoit Y, Laureys G, Dhooge C.
    Transpl Infect Dis; 2008 Feb 01; 10(1):19-23. PubMed ID: 17511814
    [Abstract] [Full Text] [Related]

  • 14. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V, Kansoy S, Küpesiz A, Aksoylar S, Kantar M, Yeşilipek A.
    Bone Marrow Transplant; 2004 May 01; 33(9):931-5. PubMed ID: 15034541
    [Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus infection in children undergoing hematopoietic stem cell transplantation in Chile.
    Paris C, Kopp K, King A, Santolaya ME, Zepeda AJ, Palma J.
    Pediatr Blood Cancer; 2009 Sep 01; 53(3):453-8. PubMed ID: 19418548
    [Abstract] [Full Text] [Related]

  • 16. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study.
    Bregante S, Bertilson S, Tedone E, Van Lint MT, Trespi G, Mordini N, Berisso G, Gualandi F, Lamparelli T, Figari O, Benvenuto F, Raiola AM, Bacigalupo A.
    Bone Marrow Transplant; 2000 Jul 01; 26(1):23-9. PubMed ID: 10918402
    [Abstract] [Full Text] [Related]

  • 17. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
    Ruutu T, Ljungman P, Brinch L, Lenhoff S, Lönnqvist B, Ringdén O, Ruutu P, Volin L, Albrechtsen D, Sallerfors B, Ebeling F, Myllylä G.
    Bone Marrow Transplant; 1997 Feb 01; 19(3):233-6. PubMed ID: 9028551
    [Abstract] [Full Text] [Related]

  • 18. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V, Ugur A, Colak D, Saba R, Tezcan G, Kupesiz A, Karadogan I, Gultekin M, Yesilipek A, Undar L.
    Jpn J Infect Dis; 2006 Aug 01; 59(4):216-21. PubMed ID: 16936338
    [Abstract] [Full Text] [Related]

  • 19. Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct).
    Bacigalupo A, Bregante S, Tedone E, Isaza A, Van Lint MT, Moro F, Trespi G, Occhini D, Gualandi F, Lamparelli T, Marmont AM.
    Bone Marrow Transplant; 1996 Nov 01; 18 Suppl 2():110-4. PubMed ID: 8932810
    [Abstract] [Full Text] [Related]

  • 20. Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.
    Jaskula E, Dlubek D, Duda D, Bogunia-Kubik K, Mlynarczewska A, Lange A.
    Biol Blood Marrow Transplant; 2009 Oct 01; 15(10):1296-305. PubMed ID: 19747638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.